Home / Companies / Bristol Myers Squibb
Company family · HQ US
Bristol Myers Squibb: medicine shortages
As of 2 Nov 2026, 18 Bristol Myers Squibb products have a reported shortage across 8 countries, covering 10 medicines.
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Long-run trend in Canada
Canada dashboardCanada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Triamcinolone | 5 | 16 Apr 2025 | Manufacturing problem | 8/16 | |
| Azacitidine | 2 | 18 Dec 2020 | Not stated | 6/16 | |
| Daclatasvir | 2 | not given | Not stated | 1/16 | |
| Ipilimumab | 2 | 12 Feb 2026 | Not stated | 1/16 | |
| Triamcinolone | 2 | 17 Apr 2025 | Manufacturing problem | 2/16 | |
| Atazanavir | 1 | not given | Not stated | 2/16 | |
| Atazanavir and Cobicistat | 1 | 3 Nov 2025 | Not stated | 1/16 | |
| Entecavir | 1 | 26 Oct 2026 | Increased demand | 8/16 | |
| Lenalidomide | 1 | 4 Sep 2026 | Other | 10/16 | |
| Nivolumab | 1 | 13 Mar 2026 | Manufacturing problem | 1/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.